U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33 books (1110 items)

1.
Ustekinumab (Stelara) Injection [Internet].

Ustekinumab (Stelara) Injection [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Nov.

Table of Contents

2.
Apremilast (Otezla) [Internet].

Apremilast (Otezla) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep.

Table of Contents

3.
Clinical Review Report: Halobetasol Propionate and Tazarotene (Duobrii): (Bausch Health, Canada Inc.): Indication: Psoriasis, moderate-to-severe plaque [Internet].

Clinical Review Report: Halobetasol Propionate and Tazarotene (Duobrii): (Bausch Health, Canada Inc.): Indication: Psoriasis, moderate-to-severe plaque [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Dec.

Table of Contents

4.
Clinical Review Report: Certolizumab Pegol (Cimzia): (UCB Canada Inc.): Indication: Treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy [Internet].

Clinical Review Report: Certolizumab Pegol (Cimzia): (UCB Canada Inc.): Indication: Treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jan.

Table of Contents

5.
Clinical Review Report: Guselkumab (Tremfya): (Janssen Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

Clinical Review Report: Guselkumab (Tremfya): (Janssen Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Mar.

Table of Contents

6.
Clinical Review Report: Ixekizumab (Taltz): (Eli Lilly Canada Inc.): Indication: Treatment of adult patients with active psoriatic arthritis who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD). Taltz can be used alone or in combination with a conventional DMARD (e.g., methotrexate) [Internet].

Clinical Review Report: Ixekizumab (Taltz): (Eli Lilly Canada Inc.): Indication: Treatment of adult patients with active psoriatic arthritis who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD). Taltz can be used alone or in combination with a conventional DMARD (e.g., methotrexate) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug.

Table of Contents

7.
Clinical Review Report: Ixekizumab (Taltz) [Internet].

Clinical Review Report: Ixekizumab (Taltz) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep.

Table of Contents

8.
Pharmacoeconomic Review Report: Ixekizumab (Taltz) [Internet].

Pharmacoeconomic Review Report: Ixekizumab (Taltz) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Sep.

Table of Contents

9.
Pharmacoeconomic Review Report: Ixekizumab (Taltz): (Eli Lilly Canada Inc.): Indication: Treatment of adult patients with active psoriatic arthritis who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD). Taltz can be used alone or in combination with a conventional DMARD (e.g., methotrexate) [Internet].

Pharmacoeconomic Review Report: Ixekizumab (Taltz): (Eli Lilly Canada Inc.): Indication: Treatment of adult patients with active psoriatic arthritis who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD). Taltz can be used alone or in combination with a conventional DMARD (e.g., methotrexate) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug.

Table of Contents

10.
Pharmacoeconomic Report: Halobetasol Propionate and Tazarotene (Duobrii): (Bausch Health, Canada Inc.): Indication: Psoriasis, moderate-to-severe plaque [Internet].

Pharmacoeconomic Report: Halobetasol Propionate and Tazarotene (Duobrii): (Bausch Health, Canada Inc.): Indication: Psoriasis, moderate-to-severe plaque [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Dec.

Table of Contents

11.
Pharmacoeconomic Review Report: Certolizumab Pegol (Cimzia): (UCB Canada Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy [Internet].

Pharmacoeconomic Review Report: Certolizumab Pegol (Cimzia): (UCB Canada Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jan.

Table of Contents

12.
Pharmacoeconomic Review Report: Risankizumab (Skyrizi): (AbbVie): Indication: For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

Pharmacoeconomic Review Report: Risankizumab (Skyrizi): (AbbVie): Indication: For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun.

Table of Contents

13.
Pharmacoeconomic Review Report: Guselkumab (Tremfya): (Janssen Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

Pharmacoeconomic Review Report: Guselkumab (Tremfya): (Janssen Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Mar.

Table of Contents

14.
Betamethasone for Adults with Scalp Psoriasis: A Review of the Clinical and Cost-Effectiveness [Internet].

Betamethasone for Adults with Scalp Psoriasis: A Review of the Clinical and Cost-Effectiveness [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Mar 30.

Table of Contents

15.
Adalimumab for Adult Patients with Plaque Psoriasis: A Review of Clinical Effectiveness [Internet].

Adalimumab for Adult Patients with Plaque Psoriasis: A Review of Clinical Effectiveness [Internet].

Peprah K, Argáez C.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jun 10.

Table of Contents

16.
Cyclosporine for Moderate to Severe Plaque Psoriasis in Adults: A Review of Clinical Effectiveness and Safety [Internet].

Cyclosporine for Moderate to Severe Plaque Psoriasis in Adults: A Review of Clinical Effectiveness and Safety [Internet].

Singh K, Argáez C.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Apr 3.

Table of Contents

17.
CADTH Canadian Drug Expert Committee Recommendation: Guselkumab (Tremfya — Janssen Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

CADTH Canadian Drug Expert Committee Recommendation: Guselkumab (Tremfya — Janssen Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb.

Table of Contents

18.
CADTH Canadian Drug Expert Committee Recommendation: Ixekizumab (Taltz — Eli Lilly Canada Inc.): Indication: Adult patients with active psoriatic arthritis (PsA) who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD) [Internet].

CADTH Canadian Drug Expert Committee Recommendation: Ixekizumab (Taltz — Eli Lilly Canada Inc.): Indication: Adult patients with active psoriatic arthritis (PsA) who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug.

Table of Contents

19.
CADTH Canadian Drug Expert Committee Recommendation: Risankizumab (Skyrizi — Abbvie): Indication: Adult patients with moderate to severe plaque psoriasis [Internet].

CADTH Canadian Drug Expert Committee Recommendation: Risankizumab (Skyrizi — Abbvie): Indication: Adult patients with moderate to severe plaque psoriasis [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May.

Table of Contents

20.
CADTH Canadian Drug Expert Committee Recommendation: Certolizumab Pegol (Cimzia — UCB Canada Inc.): Indication: Treatment of adult patients with moderate-to severe plaque psoriasis who are candidates for systemic therapy [Internet].

CADTH Canadian Drug Expert Committee Recommendation: Certolizumab Pegol (Cimzia — UCB Canada Inc.): Indication: Treatment of adult patients with moderate-to severe plaque psoriasis who are candidates for systemic therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Nov.

Table of Contents

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...